<?xml version="1.0" encoding="UTF-8" standalone="yes"?>

<!-- Copyright (c) 2004-2026 Broad Institute, Inc., Massachusetts Institute of Technology, and Regents of the University of California.  All rights reserved.
     See license terms at www.gsea-msigdb.org/gsea/license_terms_list. Please note that certain gene sets have special access terms.
-->
<MSIGDB BUILD_DATE="Jan 29, 2026" VERSION="2026.1.Hs" NAME="export">
    <GENESET STANDARD_NAME="LIANG_SILENCED_BY_METHYLATION_UP" SYSTEMATIC_NAME="M14553" HISTORICAL_NAMES="" PMID="11861364" AUTHORS="Liang G,Gonzales FA,Jones PA,Orntoft TF,Thykjaer T" GEOID="" EXACT_SOURCE="Table 1" GENESET_LISTING_URL="" EXTERNAL_DETAILS_URL="" CHIP="AFFY_HuGene" CONTRIBUTOR="John Newman" CONTRIBUTOR_ORG="University of Washington" DESCRIPTION_BRIEF="Genes up-regulated in LD419 cells (fibroblast) after treatment with decitabine (5-aza-2'-deoxycytidine) [PubChem=451668]." DESCRIPTION_FULL="Hypermethylation of the promoters of cancer-related genes is often associated with their inactivation during tumorigenesis. Several preclinical and clinical trials have been developed to use DNA methylation inhibitors, such as 5-aza-2'-deoxycytidine (5-Aza-CdR) in attempts to reactivate silenced genes in human cancers. We used high-density oligonucleotide gene expression microarrays to examine the effects of 5-Aza-CdR treatment on human fibroblast cells (LD419) and a human bladder tumor cell line (T24). Data obtained 8 days after recovery from 5-Aza-CdR treatment showed that more genes were induced in tumorigenic cells (61 genes induced; &gt;or=4-fold) than nontumorigenic cells (34 genes induced; &gt;or= 4-fold). Approximately 60% of induced genes did not have CpG islands within their 5' regions, suggesting that some genes activated by 5-Aza-CdR may not result from the direct inhibition of promoter methylation. Interestingly, a high percentage of genes activated in both cell types belonged to the IFN signaling pathway, confirming data from other tumor cell types." TAGS="" MEMBERS="D13639_at,D45917_s_at,D55696_at,D89050_at,D90224_at,J03474_at,K02765_at,L20591_at,M13955_at,M26167_rna1_at,M32053_at,M83186_at,M97936_at,U07919_at,U10687_s_at,U28727_at,U31201_cds1_at,U37283_at,U41518_at,U70063_at,U90551_at,X05232_at,X13100_s_at,X16662_at,X17042_at,X57985_rna2_at,X67325_at,X74929_s_at,Y00503_at,Y00757_at,Y08374_rna1_at,Z19574_rna1_at,Z80780_f_at" MEMBERS_SYMBOLIZED="ALDH1A3,ANXA3,ANXA8,AQP1,ASAH1,C3,CCND2,CHI3L1,COX7A1,H19,H2AC6,H2BC21,H2BC6,IFI27,KRT17,KRT19,KRT7,KRT8,LAMC2,LGMN,MAGEA4,MFAP5,MMP3,MYH3,OLR1,PAPPA,PF4V1,SAA1,SCG5,SRGN,STAT1,TIMP3,TNFSF4" MEMBERS_EZID="1116,1346,220,283120,306,3429,358,3855,3856,3872,3880,3918,4103,427,4314,4621,4973,5069,5197,5552,5641,6288,6447,653145,6772,7078,718,7292,8076,8334,8344,8349,894" MEMBERS_MAPPING="D13639_at,CCND2,894|D45917_s_at,TIMP3,7078|D55696_at,LGMN,5641|D89050_at,OLR1,4973|D90224_at,TNFSF4,7292|J03474_at,SAA1,6288|K02765_at,C3,718|L20591_at,ANXA3,306|M13955_at,KRT7,3855|M26167_rna1_at,PF4V1,5197|M32053_at,H19,283120|M83186_at,COX7A1,1346|M97936_at,STAT1,6772|U07919_at,ALDH1A3,220|U10687_s_at,MAGEA4,4103|U28727_at,PAPPA,5069|U31201_cds1_at,LAMC2,3918|U37283_at,MFAP5,8076|U41518_at,AQP1,358|U70063_at,ASAH1,427|U90551_at,H2AC6,8334|X05232_at,MMP3,4314|X13100_s_at,MYH3,4621|X16662_at,ANXA8,653145|X17042_at,SRGN,5552|X57985_rna2_at,H2BC21,8349|X67325_at,IFI27,3429|X74929_s_at,KRT8,3856|Y00503_at,KRT19,3880|Y00757_at,SCG5,6447|Y08374_rna1_at,CHI3L1,1116|Z19574_rna1_at,KRT17,3872|Z80780_f_at,H2BC6,8344" FILTERED_BY_SIMILARITY="" FOUNDER_NAMES="" REFINEMENT_DATASETS="" VALIDATION_DATASETS="" CATEGORY_CODE="C2" ORGANISM="Homo sapiens" SUB_CATEGORY_CODE="CGP"/>
</MSIGDB>
